Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: perflutren

« Back to Dashboard
Perflutren is the generic ingredient in one branded drug marketed by Lantheus Medcl and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and eight patent family members in thirty countries.

One supplier is listed for this compound.

Summary for Generic Name: perflutren

Drug Master File Entries: 0
Suppliers / Packaging: see list3

Pharmacology for Ingredient: perflutren

Clinical Trials for: perflutren

A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice
Status: Completed Condition: Cardiovascular Disease

A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure
Status: Completed Condition: Pulmonary Heart Disease

Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Status: Terminated Condition: Liver Tumors

3-D Transcranial Ultrasound Analysis Study
Status: Completed Condition: Cerebrovascular Accident; Intracranial Hypertension

Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients
Status: Recruiting Condition: Breast Cancer

Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy
Status: Recruiting Condition: Breast Cancer

Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy
Status: Active, not recruiting Condition: Breast Cancer

Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration
Status: Recruiting Condition: Exudative Macular Degeneration; Retinal Hemorrhage

Estimation of Pulmonary Vascular Resistance by Contrast Echocardiography
Status: Completed Condition: Pulmonary Arterial Hypertension

MRI / Ultrasound Fusion With Contrast-Enhanced Ultrasound Guidance
Status: Active, not recruiting Condition: Prostatic Neoplasms

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYes8,658,205<disabled>Y <disabled>
Lantheus Medcl
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYes6,033,645<disabled> <disabled>
Lantheus Medcl
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYes8,685,441<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: perflutren

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,998,107Composition comprising low density microspheres<disabled in preview>
6,521,211 Methods of imaging and treatment with targeted compositions<disabled in preview>
5,205,290 Low density microspheres and their use as contrast agents for computed tomography<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: perflutren

Country Document Number Publication Date
European Patent Office0580726Mar 29, 1995
China1083280Apr 24, 2002
Germany69229342Oct 14, 1999
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn